Compare Stocks: GMTX, EXEL, BMRN, and ARWR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$85.37 +3.2%	$83.82	$25.61 ▼ $95.49	$11.65B	1.28	1.10 million shs	1.53 million shs
BMRN BioMarin Pharmaceutical	$66.97 +3.3%	$62.24	$49.26 ▼ $70.98	$12.55B	0.24	2.30 million shs	2.52 million shs
EXEL Exelixis	$58.53 +2.9%	$54.86	$33.76 ▼ $59.11	$14.10B	0.42	2.49 million shs	2.85 million shs
GMTX Gemini Therapeutics	$78.67 +0.0%	$77.27	$1.16 ▼ $14.10	$3.41B	-0.12	189,291 shs	549,435 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+3.18%	-4.21%	-0.74%	+13.58%	+232.44%
BMRN BioMarin Pharmaceutical	+3.29%	+2.07%	+11.64%	+18.59%	+13.34%
EXEL Exelixis	+2.88%	+4.33%	+6.30%	+11.51%	+57.42%
GMTX Gemini Therapeutics	+0.03%	-4.54%	+2.17%	+11.83%	+31.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$85.37 +3.2%	$83.82	$25.61 ▼ $95.49	$11.65B	1.28	1.10 million shs	1.53 million shs
BMRN BioMarin Pharmaceutical	$66.97 +3.3%	$62.24	$49.26 ▼ $70.98	$12.55B	0.24	2.30 million shs	2.52 million shs
EXEL Exelixis	$58.53 +2.9%	$54.86	$33.76 ▼ $59.11	$14.10B	0.42	2.49 million shs	2.85 million shs
GMTX Gemini Therapeutics	$78.67 +0.0%	$77.27	$1.16 ▼ $14.10	$3.41B	-0.12	189,291 shs	549,435 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+3.18%	-4.21%	-0.74%	+13.58%	+232.44%
BMRN BioMarin Pharmaceutical	+3.29%	+2.07%	+11.64%	+18.59%	+13.34%
EXEL Exelixis	+2.88%	+4.33%	+6.30%	+11.51%	+57.42%
GMTX Gemini Therapeutics	+0.03%	-4.54%	+2.17%	+11.83%	+31.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$98.42	15.28% Upside
BMRN BioMarin Pharmaceutical	2.74	Moderate Buy	$89.17	33.16% Upside
EXEL Exelixis	2.35	Hold	$50.07	-14.46% Downside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GMTX, EXEL, BMRN, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/1/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$88.00 ➝ $90.00
9/1/2026	EXEL Exelixis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/31/2026	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$100.00
8/31/2026	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
8/31/2026	BMRN BioMarin Pharmaceutical	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$104.00 ➝ $105.00
8/31/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$59.00 ➝ $60.00
8/26/2026	BMRN BioMarin Pharmaceutical	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$88.00
8/19/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/18/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$669.50M	17.96	$0.12 per share	692.96	$3.31 per share	25.79
BMRN BioMarin Pharmaceutical	$3.22B	4.02	$2.95 per share	22.73	$32.66 per share	2.05
EXEL Exelixis	$2.32B	6.25	$3.11 per share	18.79	$7.44 per share	7.87
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	N/A
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	181.00	12.31	0.46	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	18.41	15.78	1.69	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A

Latest GMTX, EXEL, BMRN, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
EXEL Exelixis	N/A	3.46	3.38
GMTX Gemini Therapeutics	N/A	71.49	71.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
GMTX Gemini Therapeutics	75.42%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
GMTX Gemini Therapeutics	12.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable

GMTX, EXEL, BMRN, and ARWR Headlines

Recent News About These Companies

FDA reversals leave investors worrying about the fates of other experimental drugs

March 6, 2026 | cnbc.com

What Is Gemini? Everything You Should Know About Google's AI Tool

October 17, 2024 | cnet.com

Google Gemini could soon get a lot more useful on your phone

July 31, 2024 | androidpolice.comA

Gemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?

July 22, 2024 | businessinsider.com

ChatGPT vs. Microsoft Copilot vs. Gemini: Which is the best AI chatbot?

May 23, 2024 | zdnet.comZ

Gemini Monthly Horoscope: May 2024

May 2, 2024 | pedestrian.tvP

Google's Gemini AI Will Work On Your Pixel 2 XL—Android 10, 11 Devices Now Supported

April 28, 2024 | techtimes.comT

Comparing ChatGPT 3.5, Microsoft Bing, and Google Gemini in diagnosing cases of neuro-ophthalmology

April 17, 2024 | ophthalmologytimes.comO

Google's public release of Gemini 1.5 should build trust, Deutsche Bank says

April 17, 2024 | seekingalpha.com

Google Gemini: Everything you need to know about Google's Answer to ChatGPT – Updated December 2023

December 9, 2023 | androidheadlines.comA

Gemini Review 2023: Pros, Cons and How It Compares

November 16, 2023 | nerdwallet.comN

Yesterday's Gemini Horoscope

October 5, 2023 | yourtango.comY

Gemini Tarot Horoscopes: October 2023

October 3, 2023 | glamour.comG

Yearly Gemini Tarot Card Reading

August 28, 2023 | yourtango.comY

Move over Bard, Google's next big AI product is coming this fall

August 19, 2023 | androidauthority.comA

Radar In Space: The Gemini Rendezvous Radar

July 27, 2023 | hackaday.comH

Sun Transit in Gemini- The twins love the Sun’s visit

July 13, 2023 | prokerala.comP

Sun Transit in Gemini: Sun with Dual energies?

July 5, 2023 | prokerala.comP

Gemini Allows Withdrawals for Voyager Customers Whose Funds Have Been Trapped since Bankruptcy

June 26, 2023 | coinspeaker.com

(SPAC) Special Purpose Acquisition Investigation: PRDS, GMTX, SNTI, TNGX - Contact Shareholder Rights Law Firm Johnson Fistel

June 24, 2023 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX, EXEL, BMRN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$85.37 +2.63 (+3.18%)

Closing price 09/2/2026 04:00 PM Eastern

Extended Trading

$85.00 -0.37 (-0.43%)

As of 07:22 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

BioMarin Pharmaceutical NASDAQ:BMRN

$66.97 +2.13 (+3.29%)

Closing price 09/2/2026 04:00 PM Eastern

Extended Trading

$66.85 -0.12 (-0.18%)

As of 07:16 AM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$58.53 +1.64 (+2.88%)

Closing price 09/2/2026 04:00 PM Eastern

Extended Trading

$58.73 +0.20 (+0.33%)

As of 07:36 AM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Gemini Therapeutics NASDAQ:GMTX

$78.67 +0.02 (+0.03%)

As of 09/1/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GMTX, EXEL, BMRN, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GMTX, EXEL, BMRN, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GMTX, EXEL, BMRN, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX, EXEL, BMRN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Gemini Therapeutics NASDAQ:GMTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GMTX, EXEL, BMRN, and ARWR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GMTX, EXEL, BMRN, and ARWR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GMTX, EXEL, BMRN, and ARWR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX, EXEL, BMRN, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Gemini Therapeutics NASDAQ:GMTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools